Starpharma is committed to developing innovative products that will create enduring global impact. Our corporate governance principles and Code of Conduct provide a framework for ethical and responsible behaviour at all levels of our organisation.

 In Australia, sustainability reporting requirements are being phased in over three years based on the type and size of the reporting entity. At this stage, under the Corporations Act, Starpharma does not meet the thresholds in section 292A for sustainability reporting.

Notwithstanding the Corporations Act requirements, Starpharma has prepared this ESG Report for FY25. This report aims to provide information about sustainability-related risks and opportunities important to Starpharma and our stakeholders. Our focus is on current and emerging issues whether real, perceived, or potential, throughout the development, registration, production, and marketing of pharmaceutical products.

The report covers the year ending 30 June 2025 and encompasses the operations of all companies within the Starpharma group during that period. It is published alongside our Annual Report, which provides information on our activities, progress, governance arrangements, and financial performance.

Starpharma has established formal policies and procedures, including an Environmental Policy and a Climate Change Position Statement, to operate responsibly and minimise the environmental impact of our work, including operations, research and development, and product marketing.

We have implemented measures to manage water consumption, waste and recycling, and greenhouse gas emissions. Our staff understand and comply with these initiatives. Although our global environmental risk exposure is small, Starpharma will continue to monitor, report and take action wherever necessary to mitigate our impact.

We are proud of our innovative, accountable, high-performing and ethical culture. Our set of Valued Behaviours fosters effective collaboration among all employees who understand and appreciate the broader community's benefits from their work.

We strive to create a workplace that prioritises equality, safety, health and wellbeing. We have implemented a comprehensive suite of policies and procedures to ensure these outcomes.

Great Place to Work^® certification

Starpharma was delighted to achieve Great Place to Work® certification for the third consecutive year in FY25. This recognition validates our team's positive workplace and company culture, as well as our commitment to inclusivity and diversity.

Starpharma is committed to providing consumers and patients with safe access to our products at all stages of the development process.

Our products undergo rigorous development and evaluation, including preclinical testing and clinical trials, and are labelled and marketed pursuant to high-quality standards and regulations specific to each geographic region. The Company conducts post-market surveillance and vigilance activities on all marketed products.

Although Starpharma has a relatively small number of suppliers, we prioritise responsible and ethical practices across our operations. We expect our suppliers to uphold high ethical standards and source from sustainable vendors.

Starpharma is committed to the principles underpinning best practices in corporate governance, emphasising general corporate compliance and ethical business, financial and social practices. Our robust corporate governance policies serve as a guide for our Company's actions and decision-making.